Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background Circulating tumor DNA (ctDNA) is a promising technology for treatment selection, prognostication, and surveillance after definitive therapy. Its use in the perioperative setting for patients with metastatic disease has not been well studied. We characterize perioperative plasma ctDNA and its association with progression-free survival (PFS) in patients undergoing surgery for peritoneal metastases.Patients and methods We recruited 71 patients undergoing surgery for peritoneal metastases and evaluated their plasma with a targeted 73-gene ctDNA next-generation sequencing test before and after surgery. The association between perioperative ctDNA, as well as other patient factors, and PFS was evaluated by Cox regression.Results ctDNA was detectable in 28 patients (39.4%) preoperatively and in 37 patients (52.1%) postoperatively. Patients with high ctDNA [maximum somatic variant allele fraction (MSVAF) > 0.25%] had worse PFS than those with low MSVAF (< 0.25%) in both the pre- and postoperative settings (median 4.8 vs. 19.3 months, p < 0.001, and 9.2 vs.15.0 months, p = 0.049, respectively; log-rank test). On multivariate analysis, high-grade histology [hazard ratio (HR) 3.42, p = 0.001], incomplete resection (HR 2.35, p = 0.010), and high preoperative MSVAF (HR 3.04, p = 0.001) were associated with worse PFS. Patients with new postoperative alterations in the context of preoperative alteration(s) also had a significantly shorter PFS compared with other groups (HR 4.28, p < 0.001).Conclusions High levels of perioperative ctDNA and new postoperative ctDNA alterations in the context of preoperative alterations predict worse outcomes in patients undergoing resection for peritoneal metastases. This may highlight a role for longitudinal ctDNA surveillance in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Despite its uncharacterized clinical significance, VUS may reflect tumor growth and disease progression.26”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
tidyverse: Easily Install and Load the 'Tidyverse'
Wickham, H. (2016) · CRAN: Contributed Packages · doi:10.32614/cran.package.tidyverse · Cited by 1,381
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Chua, T. C., Moran, B. J., Sugarbaker, P. H., Levine, E. A., Glehen, O., Gilly, F. N., Baratti, D., Deraco, M., Elias, D., Sardi, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7166 · Cited by 1,071
Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033
Yan, T. D., Deraco, M., Baratti, D., Kusamura, S., Elias, D., Glehen, O., Gilly, F. N., Levine, E. A., Shen, P., Mohamed, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9640 · Cited by 696
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695
Self-citationOdegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., Fairclough, S. R., Zill, O. A., Sikora, M., Mokhtari, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3831 · Cited by 435
Self-citationCirculating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421
Cited by
Flory, A., Kruglyak, K. M., Tynan, J. A., McLennan, L. M., Rafalko, J. M., Fiaux, P. C., Hernandez, G. E., Marass, F., Nakashe, P., Ruiz-Pérez, C. A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266623 · Cited by 66
Sullivan, B. G., Lo, A., Yu, J., Gonda, A., Dehkordi‐Vakil, F., Dayyani, F., & Senthil, M. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12399-y · Cited by 49
Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., Kim, A. H., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102697 · Cited by 37
Biomarkers in high grade serous ovarian cancer
Bates, M., Mohamed, B. M., Lewis, F., O’Toole, S. A., & O’Leary, J. J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189224 · Cited by 33
Dhiman, A., Kothary, V., Witmer, H. D. D., Bregio, C., Sood, D., Ong, C. T., Polite, B., Eng, O. S., Shergill, A., & Turaga, K. K. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005856 · Cited by 25
Metadata
- Authors
- Baumgartner, J. M., Riviere, P., Lanman, R. B., Kelly, K. J., Veerapong, J., Lowy, A. M., & Kurzrock, R.
- Affiliations
- University of California San Diego (US)
- Guardant (United States) (US)
- Corresponding author
- Baumgartner, Joel M.
- ORCID
- Venue
- Annals of Surgical Oncology
- Published
- 2020-08-06
- Volume
- 27
- Issue
- 9
- Pages
- 3259-3267
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- PMC
- PMC7470602
- OpenAlex
- W3047401551
- Cited by
- 25
- References
- 29
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 1 · 2020: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Annals of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Joan and Irwin Jacobs Fund philanthropic fund
- National Cancer Institute (CA023100)
- National Institutes of Health (TL1TR001443)
- Guardant Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- circulating tumor DNA, liquid biopsy, peritoneal carcinomatosis, progression-free survival, incomplete resection, histologic grade, prognostic factors, colorectal cancer
- MeSH terms
- Liquid Biopsy, Circulating Tumor DNA, Female, Humans, Male, Middle Aged, Mutation, Peritoneal Neoplasms, Postoperative Period, Prognosis, Biomarkers, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. https://app.cochat.ai/papers/10.1245/s10434-020-08331-x
- The paper
- Baumgartner, J. M., Riviere, P., Lanman, R. B., Kelly, K. J., Veerapong, J., Lowy, A. M., & Kurzrock, R. (2020). Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-020-08331-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.